Generation of an anti-CD5 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology

IF 0.8 4区医学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Stem cell research Pub Date : 2025-05-06 DOI:10.1016/j.scr.2025.103731

Shuoting Wang , Xinrui Guo , Han Yan , Tiancheng Zhou , Jiajun Liu

引用次数: 0

Abstract

The anti-CD5 chimeric antigen receptor (CAR) is a genetically engineered immune cell therapy developed to target CD5-associated hematologic malignancies, such as T-cell lymphoma and leukemia. Using CRISPR/Cas9-mediated gene targeting, we generated an anti-CD5 CAR knock-in human induced pluripotent stem cell (iPSC) line that stably expresses the CAR construct and is detectable via FLAG tag and GFP markers. This engineered cell line maintains stem cell morphology, displays a normal karyotype, and exhibits robust expression of pluripotency markers while retaining differentiation potential.

查看原文本刊更多论文

使用CRISPR/Cas9技术生成抗cd5 CAR敲入的人诱导多能干细胞系

抗cd5嵌合抗原受体（CAR）是一种基因工程免疫细胞疗法，用于靶向cd5相关的血液恶性肿瘤，如t细胞淋巴瘤和白血病。利用CRISPR/ cas9介导的基因靶向，我们产生了一种抗cd5 CAR敲入的人诱导多能干细胞（iPSC）系，该系稳定表达CAR构建体，并可通过FLAG标签和GFP标记检测。该工程细胞系保持干细胞形态，显示正常核型，并在保持分化潜力的同时表现出多能性标记的强大表达。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stem cell research 生物-生物工程与应用微生物

CiteScore

2.20

自引率

8.30%

发文量

338

审稿时长

55 days

期刊介绍： Stem Cell Research is dedicated to publishing high-quality manuscripts focusing on the biology and applications of stem cell research. Submissions to Stem Cell Research, may cover all aspects of stem cells, including embryonic stem cells, tissue-specific stem cells, cancer stem cells, developmental studies, stem cell genomes, and translational research. Stem Cell Research publishes 6 issues a year.